Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [ 14C]dapivirine for 7 days

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 3, 2008, Pages 909-914

  Nuttall, Jeremy P ^a   Thake, Daryl C ^b   Lewis, Mark G ^c   Ferkany, John W ^d   Romano, Joseph W ^a   Mitchnick, Mark A ^e  

^a INTERNATIONAL PARTNERSHIP FOR MICROBICIDES   (United States)

^b Seventh Wave Pathology and Biotechnical Solutions   (United States)

^c BIOQUAL INC   (United States)

^d PharmaDirections   (United States)

^e Particle Sciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPIVIRINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FORMULATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; RADIOACTIVITY; RHESUS MONKEY;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; CARBON RADIOISOTOPES; CERVIX UTERI; FEMALE; HIV REVERSE TRANSCRIPTASE; MACACA MULATTA; PYRIMIDINES; RABBITS; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; VAGINA; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 40549106089     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00330-07     Document Type: Article

References (12)

1. Borkow, G., J. Barnard, T.-M. Nguyen, A. Belmonte, M. A. Weinberg, and M. A. Parniak. 1997. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J. Virol. 71:3023-3030.
2. Cohen, M. S. 2004. HIV and sexually transmitted diseases: lethal synergy. Top. HIV Med. 12:104-107.
3. Das, K., A. D. Clark, Jr., P. J. Lewi, J. Heeres, M. R. De Jonge, L. M. Koymans, H. M. Vinkers, F. Daeyaert, D. W. Ludovici, M. J. Kukla, B. De Corte, R. W. Kavash, C. Y. Ho, H. Ye, M. A. Lichtenstein, K. Andries, R. Pauwels, M. P. De Bethune, P. L. Boyer, P. Clark, S. H. Hughes, P. A. Janssen, and E. Arnold. 2004. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 47:2550-2560.
4. Dayal, M. B., J. Wheeler, C. Williams, J., and K. T. Barnhart. 2003. Disruption of the upper female reproductive tract epithelium by nonoxynol-9. Contraception 68:273-279.
5. D'Cruz, O. J., and F. M. Uckun. 2006. Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. J. Antimicrob. Chemother. 57:411-423.
6. Di Fabio, S., J. Van Roey, G. Giannini, G. van den Mooter, M. Spada, A. Binelli, M. Pirillo, E. Germinario, F. Belardelli, M.-P. de Bethune, and S. Vella. 2003. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS 17:1597-1604.
7. Fletcher, P., Y. Kiselyeva, G. Wallace, J. Romano, G. Griffin, L. Margolis, and R. Shattock. 2005. The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J. Virol. 79:11179-11186.
8. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
9. Jespers, V. A., J. M. Van Roey, G. I. Beets, and A. M. Buva. 2007. Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers. J. Acquir. Immune Defic. Syndr. 44:154-158.
10. National Institute of Allergy and Infectious Diseases. May 2006. HIV infection in women. http://www.niaid.nih.gov/factsheets/womenhiv.htm.
11. Tarby, C. M. 2004 Recent advances in the development of next generation non-nucleoside reverse transcriptase inhibitors. Curr. Top. Med. Chem. 4:1045-1057.
12. Van Herrewege, Y., J. Michiels, J. Van Roey, K. Fransen, L. Kestens, J. Balzarini, P. Lewi, G. Vanham, and P. Janssen. 2004. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob. Agents Chemother. 48:337-339.